Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma

Kazia Therapeutics CEO Dr James Garner chats to Proactive’s Andrew Scott about recent news from its GBM AGILE pivotal study for glioblastoma. Dr Garner also discusses data received from its brain metastases study and the commercial prospects when it comes to brain metastases.